F2R and intracranial hemorrhage: Moreover, treatment with vorapaxar (a PAR-1 antagonist) on top of DAPT significantly reduced the composite endpoint of myocardial infarction, stroke, and cardiovascular death in ACS patients in the TRACER trial, but also significantly increased the risk of bleeding including intracranial hemorrhage [29].